Forbion Capital Fund IV Cooperatief U.A.'s Form 4 filing
NewAmsterdam Pharma Co N.V.NAMS · filed Dec 18, 2024
- Accession no.
- 0000950170-24-137893
- Filed
- Dec 18, 2024, 4:15 PM ET
- Trade date
- Dec 16-17, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 3 non-derivative transactions. Open-market sales total $3.00M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Forbion Capital Fund IV Cooperatief U.A.CIK 0001823747 | 10% Owner |
| Forbion Growth Opportunities Fund I Cooperatief U.A.CIK 0001911047 | 10% Owner |
| Forbion Growth Management B.V.CIK 0001918318 | 10% Owner |
| Forbion IV Management B.V.CIK 0002005384 | 10% Owner |
| ForGrowth NAP B.V.CIK 0002005407 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 16, 2024 | Ordinary Shares | SSaleDisposed | −1,096 | $25.00 | −$27,400 | 11,123,614 | Indirect | |
| Dec 17, 2024 | Ordinary Shares | SSaleDisposed | −66,648 | $25.60F4 | −$1,706,315.43 | 11,056,966 | Indirect | |
| Dec 17, 2024 | Ordinary Shares | SSaleDisposed | −47,736 | $26.45F5 | −$1,262,440.58 | 11,009,230 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F4
Represents 29,272 shares sold on behalf of Forbion Growth I and 37,376 shares sold on behalf of Forbion IV. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.00 to $25.99. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Following the reported transaction, of the 11,056,966 Ordinary Shares beneficially owned by ForGrowth, 652,173 shares are directly owned by ForGrowth on behalf of Forbion Growth I, and 10,404,793 are held by PoolCo and are allocated to ForGrowth, of which 4,203,740 shares are beneficially owned by Forbion Growth I and 6,201,053 shares are beneficially owned by Forbion IV.
Referenced by the price of 1 transaction in Table I.
- F5
Represents 20,966 shares sold on behalf of Forbion Growth I and 26,770 shares sold on behalf of Forbion IV. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $26.00 to $25.855. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Following the reported transaction, of the 11,009,230 Ordinary Shares beneficially owned by ForGrowth, 652,173 shares are directly owned by ForGrowth on behalf of Forbion Growth I, and 10,357,057 are held by PoolCo and are allocated to ForGrowth, of which 4,182,774 shares are beneficially owned by Forbion Growth I and 6,174,283 shares are beneficially owned by Forbion IV.
Referenced by the price of 1 transaction in Table I.